One study saw an ORR of 45% (10 of 22 patients)
36% of patients (8 of 22) saw a complete response
9% of patients (2 of 22) saw a partial response
FOR 30% of PATIENTS (3 of 10), their cancer continued to respond to treatment without growing or spreading for at least 6 months after initial response (DOR)
The other study saw an ORR of 34% (13 of 38 patients)
26% of patients (10 of 38) saw a complete response
8% of patients (3 of 38) saw a partial response
FOR 23% of PATIENTS (3 of 13), their cancer continued to respond to treatment without growing or spreading for at least 6 months after initial response (DOR)
You may know DANYELZA as Hu3F8, the name used in one of the clinical studies

“When Michael saw no benefit to all the treatments he had had, we found another treatment option called DANYELZA that would hopefully work for him.”